Last quarter (Q3 2023), SAGE Therapeutics's total revenue was $2.72M, an increase of 56.18% from the same quarter last year. In Q3, SAGE Therapeutics's net income was $-199.82M. See SAGE Therapeutics’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Dec 22	Dec 21	Dec 20	Dec 19	Dec 18
Total Revenue	$ 11.33M	$ 7.69M	$ 6.31M	$ 1.11B	$ 6.87M	$ 90.27M
Cost of Revenue	-	-	-	$ 565.00K	$ 400.00K	$ 0.00
Gross Profit	$ 11.35M	$ 7.69M	$ 6.31M	$ 1.11B	$ 6.47M	$ 90.27M
Operating Expense	$ 703.03M	$ 554.67M	$ -467.22M	$ 489.67M	$ 714.59M	$ 483.51M
Operating Income	$ -691.27M	$ -546.99M	$ -460.91M	$ 623.97M	$ -708.12M	$ -393.24M
Net Non Operating Interest Income Expense	$ 36.07M	$ 14.19M	$ 2.88M	$ 9.60M	$ 27.80M	$ 20.33M
Other Income Expense	$ 320.00K	$ -15.00K	$ -134.00K	$ -27.49M	$ 82.00K	$ 22.00K
Pretax Income	$ -653.71M	$ -531.16M	$ -457.89M	$ 606.07M	$ -680.24M	$ -372.88M
Tax Provision	-	-	-	-	-	-
Earnings From Equity Interest Net Of Tax	-	-	-	-	-	-
Net Income Common Stockholders	$ -654.12M	$ -532.78M	$ -457.89M	$ 606.07M	$ -680.24M	$ -372.88M
Basic EPS	$ -13.05	$ -8.98	$ -7.80	$ 11.66	$ -13.38	$ -8.08
Diluted EPS	$ -10.98	$ -8.98	$ -7.80	$ 11.43	$ -13.38	$ -8.08
Basic Average Shares	$ 238.66M	$ 59.31M	$ 58.67M	$ 51.98M	$ 50.83M	$ 46.12M
Diluted Average Shares	$ 238.66M	$ 59.31M	$ 58.67M	$ 53.00M	$ 50.83M	$ 46.12M
Dividend Per Share	-	-	-	-	-	-
Total Operating Income As Reported	-	-	-	-	-	-
Reported Normalized Basic E P S	-	-	-	-	-	-
Reported Normalized Diluted E P S	-	-	-	-	-	-
Rent Expense Supplemental	-	-	-	-	-	-
Total Expenses	$ 703.03M	$ 554.67M	$ -467.22M	$ 490.23M	$ 714.99M	$ 483.51M
Net Income From Continuing And Discontinued Operation	$ -655.93M	$ -532.78M	$ -457.89M	$ 606.07M	$ -680.24M	$ -372.88M
Normalized Income	$ -250.59M	-	-	$ 633.82M	$ -680.24M	$ -372.88M
Interest Expense	-	-	-	-	-	-
EBIT	$ -669.33M	$ -531.16M	$ -460.77M	$ 623.97M	$ -708.12M	$ -393.24M
EBITDA	$ -668.08M	$ -530.06M	$ -456.57M	$ 626.60M	$ -705.84M	$ -392.10M

Currency in USD

SAGE Therapeutics Earnings and Revenue History

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing